

# VGX-1027

**Catalog No: tcsc2737**



## Available Sizes

**Size:** 10mg

**Size:** 50mg



## Specifications

**CAS No:**

6501-72-0

**Formula:**

$C_{11}H_{11}NO_3$

**Pathway:**

Immunology/Inflammation

**Target:**

Interleukin Related

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 56$  mg/mL (272.89 mM)

**Alternative Names:**

GIT 27

**Observed Molecular Weight:**

205.21


## Product Description

VGX-1027(GIT27) is an isoxazole compound that exhibits various immunomodulatory properties; reduce the secretion of IL-1beta, TNF-alpha and IL-10 from purified murine macrophages.

IC50 value:

Target: immunomodulator

Administration of VGX-1027 to NOD mice with spontaneous or accelerated forms of diabetes induced either by injection of cyclophosphamide or by transfer of spleen cells from acutely diabetic syngeneic donors markedly reduced the cumulative incidence of diabetes and insulinitis. In addition, VGX-1027 given either i.p. or p.o. to CBA/H mice made diabetic with multiple low doses of streptozotocin successfully counteracted the development of destructive insulinitis and hyperglycemia [1]. VGX-1027 appeared to spare T cell function as it was unable to modify the proliferation and/or secretion of IL-2, IFN-gamma and IL-4 induced in purified murine CD4<sup>+</sup> T cells from stimulation with either CD3+CD28 or ConA [2]. VGX-1027 inhibited both proliferation of enterobacterial antigen-reactive CD4<sup>+</sup>CD25<sup>-</sup> T cells in vitro and the development of clinical and histological signs of colitis in vivo [3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!